0
0.0
Feb 1, 2024
02/24
by
BBCNEWS
tv
eye 0
favorite 0
quote 0
but novo nordisk�*s rise is also having a big impact at home in denmark.ray reports from copenhagen. if you thought lego or a maersk were the biggest companies from denmark, you would be wrong. dwarfing them all is novo nordisk, the pharmaceutical firm behind blockbuster drugs ozempic. the first of a new generation of treatments expected to turbo—charge weight loss. it�*s an injection for those severely overweight. while ozempic treats diabetes and both contain the drugs chemically tied, which lowers appetite. it was in 2018, three years before... this 45—year—old says he�*s lost more than 60 kilos over two years. it comes with four dosages. he spends almost $300 a month on his prescription, but says it�*s been life changing. i have tried all of the different kinds of diets and reprogramming my way of eating and all of that a million times. before i looked at the future in a dark way. i thought maybe i�*m not getting to be 60 years, maybe i�*m not seeing my grandkids. the biggest change for me is that i�*m looking at the future way brighter than before. re
but novo nordisk�*s rise is also having a big impact at home in denmark.ray reports from copenhagen. if you thought lego or a maersk were the biggest companies from denmark, you would be wrong. dwarfing them all is novo nordisk, the pharmaceutical firm behind blockbuster drugs ozempic. the first of a new generation of treatments expected to turbo—charge weight loss. it�*s an injection for those severely overweight. while ozempic treats diabetes and both contain the drugs chemically tied,...
0
0.0
Feb 1, 2024
02/24
by
BBCNEWS
tv
eye 0
favorite 0
quote 0
but novo nordisk s rise is also having a big impact at home in denmark.ne murray reports from copenhagen. if you thought lego or a maersk were the biggest companies from denmark, you would be wrong. torquing them all is novo nordisk, the pharmaceutical firm behind blockbuster drugs was on deck. the first of a new generation of treatments expected to turbo—charge weight loss. it's an injection for those severely overweight. while it was peak treats diabetes and both contain the drugs chemically tied, which lowers appetite. it drugs chemically tied, which lowers appetite.— lowers appetite. it was in 2018, three _ lowers appetite. it was in 2018, three years - lowers appetite. it was in l 2018, three years before... might this 45—year—old says he's lost more than 60 kilos over two years. it comes with four dosages. he over two years. it comes with four dosages.— over two years. it comes with four dosages. he spends on mus $300 a month _ four dosages. he spends on mus $300 a month on _ four dosages. he spends on mus $300 a month on his _ $300 a month on his d
but novo nordisk s rise is also having a big impact at home in denmark.ne murray reports from copenhagen. if you thought lego or a maersk were the biggest companies from denmark, you would be wrong. torquing them all is novo nordisk, the pharmaceutical firm behind blockbuster drugs was on deck. the first of a new generation of treatments expected to turbo—charge weight loss. it's an injection for those severely overweight. while it was peak treats diabetes and both contain the drugs...
0
0.0
Feb 2, 2024
02/24
by
CNBC
tv
eye 0
favorite 0
quote 0
novo nordisk is the top pick any others >> we like novo nordisk.e are overweight on astrazeneca and sanofi sanofi gave back a bit yesterday on the weaker quarter. astrazeneca is one we are positive on the pipeline however, you know, really novo is the easy story. the one where the path forward is very clean and there's clinical catalyst to be excited about. >> very clear and as we spoke to the ceo, he was feeling good emily, thank you for joining me on set today emily field, director and head of european pharmaceuticals from barclays >>> a quick look at european markets and how they are faring today. we did the week to date, but all of the markets are leaning toward the green today as we digest a big week of data and earnings and central bank meetings bank of england meeting. ftse 100 up .40% after they decided to keep rates unchanged, but opened the door to rate cuts amazon and meta. that is it for our show. i'm joumanna bercetche "worldwide exchange" is coming up next. hi, i'm kim, and i lost 67 pounds on golo. when i go out with people, they exp
novo nordisk is the top pick any others >> we like novo nordisk.e are overweight on astrazeneca and sanofi sanofi gave back a bit yesterday on the weaker quarter. astrazeneca is one we are positive on the pipeline however, you know, really novo is the easy story. the one where the path forward is very clean and there's clinical catalyst to be excited about. >> very clear and as we spoke to the ceo, he was feeling good emily, thank you for joining me on set today emily field,...
0
0.0
Feb 6, 2024
02/24
by
BLOOMBERG
tv
eye 0
favorite 0
quote 0
novo nordisk said it would buy these production facilities to expand ozempic production and there areuestions about the day on eli lilly's call as investors want to know how lily is ramping up supply. both companies have invested billions already. lily has already invested billions. the question is how long it will take for those new plans and that supply capacity to, online. that is what investors and analysts are wanting to know today. the answer is it does take time so we will not get immediate supply like we would like. sonali: there was a little bit of shade thrown on the call, this idea they intend holding catalan accountable to their contracts. how do you see the dispute playing out? madison: it is interesting. we were trying to figure out what this deal is going to entail. catalan is a huge contract manufacturer, i think they are the world's biggest contract manufacturer for gene therapies, they have deals with a lot of big drugmakers. there the biggest producers for obesity and diabetes drugs. we are try to figure out how this will affect other drugmakers and that is somethin
novo nordisk said it would buy these production facilities to expand ozempic production and there areuestions about the day on eli lilly's call as investors want to know how lily is ramping up supply. both companies have invested billions already. lily has already invested billions. the question is how long it will take for those new plans and that supply capacity to, online. that is what investors and analysts are wanting to know today. the answer is it does take time so we will not get...
0
0.0
Feb 1, 2024
02/24
by
BBCNEWS
tv
eye 0
favorite 0
quote 0
danish drug maker novo nordisk has seen its stock market value soar on the success of its obesity and's now europe's most valuable company — with a market value of half a trillon dollars. on wednesday it revealed that profits surged 50 percent last year to 12 billion dollars. and the growth in the market for weight loss drugs may be onlyjust beginning. novo nordisk the pharmaceutical firm behind blockbuster drugs wegovy ozempic, the first generation of treatment expected to tackle weight loss, given as injections to those severely overweight. ozempic treat diabetes and both contain a drug that lowers appetite. it was in 2018, we started... a drug that lowers appetite. it | was in 2018, we started... this 45-year-old — was in 2018, we started... this 45-year-old says _ was in 2018, we started... this 45-year-old says he _ was in 2018, we started... this 45-year-old says he has - was in 2018, we started... this 45—year—old says he has lost more than 60 kilos over two years. it more than 60 kilos over two ears. . ., , more than 60 kilos over two ears. _, , ., . years. it comes in a packa
danish drug maker novo nordisk has seen its stock market value soar on the success of its obesity and's now europe's most valuable company — with a market value of half a trillon dollars. on wednesday it revealed that profits surged 50 percent last year to 12 billion dollars. and the growth in the market for weight loss drugs may be onlyjust beginning. novo nordisk the pharmaceutical firm behind blockbuster drugs wegovy ozempic, the first generation of treatment expected to tackle weight...
0
0.0
Feb 21, 2024
02/24
by
KNTV
tv
eye 0
favorite 0
quote 0
nordisk and eli lilly. what do you say to people who say 12 is too young to put a child on a weight loss medication >> yeah, i think that it's about education for the family, because i think there's a lot of perception about using the medication, about for really appearances. that's not what we're here to do what we're here to do is to help your patient, a 12-year-old be healthy. >> reporter: but there are possible side effects like nausea, vomiting, and abdominal pain doctors at uc irvine say they're worried these drugs could affect kids' growth from undereating or be abused by those with eating disorders or in sports some also question whether kids need to use these drugs long-term. what do you say to people who think the data is not there, that we don't know the long-term effects for young people >> yeah, so these medications, i think are reassuring in that they've been around over a decade. >> reporter: in a statement, wegovy's maker novo nordisk says its studies found their medicines did not appear to
nordisk and eli lilly. what do you say to people who say 12 is too young to put a child on a weight loss medication >> yeah, i think that it's about education for the family, because i think there's a lot of perception about using the medication, about for really appearances. that's not what we're here to do what we're here to do is to help your patient, a 12-year-old be healthy. >> reporter: but there are possible side effects like nausea, vomiting, and abdominal pain doctors at uc...
0
0.0
Feb 1, 2024
02/24
by
CNBC
tv
eye 0
favorite 0
quote 0
the focus is on novo nordisk with the obesity drug. wonder what company like your company can present on the successful obesity drugs do you see this as a challenge or opportunity for the business? >> i think compared to other companies, the link to siemens u.s. is less direct than potentially diabetes for companies. companies are focused on diabetes in general, the strength of siemens is to fight the non-communicable diseases. the longer people live healthy lives, but also the more important chronic disease becomes, the more important our products become. the novo nordisk is one example of the broad innovation for us when there is a drug against alzheimer's, you need the diagnosis from our equipment when there is a new implant, then you need to guide the surgery. this is a topic which always helps our growth in the novo nordisk case, it is a comparable indirect one. >> we are seeing shares moving higher this morning after the latest results when you look at the performance in 2023, siemens is among the top shorted stocks in europe whe
the focus is on novo nordisk with the obesity drug. wonder what company like your company can present on the successful obesity drugs do you see this as a challenge or opportunity for the business? >> i think compared to other companies, the link to siemens u.s. is less direct than potentially diabetes for companies. companies are focused on diabetes in general, the strength of siemens is to fight the non-communicable diseases. the longer people live healthy lives, but also the more...
0
0.0
Feb 12, 2024
02/24
by
BLOOMBERG
tv
eye 0
favorite 0
quote 0
by novo nordisk and others. -- created by novo nordisk and others. how is that impacting you?phan: we are partnering with the leading brands. plunger, ways to get -- protect the drug and get the drug injected into the body. sonali: how much does it matter to have more subsidy for an industry like that via insurance, and how would that be impacting you? stephan: clearly there is tremendous growth especially in the u.s., the model is at a high price point. overtime discounts being made. i think you have the ceo for novo nordisk on last week and explained that very well. what this applies to up-and-down the supply chain is investing massively into supply. we alone have invested $180 million and of course our customers invest many multiples of that as these drugs promise a benefit. right now it is much more demand than the supply chain can supply. sonali: i'm glad you brought out the supply chain because with so much geopolitical tension there was a lot of concern this could create every acceleration of inflation. how concerned are you? stephan: we see inflation muted, especially
by novo nordisk and others. -- created by novo nordisk and others. how is that impacting you?phan: we are partnering with the leading brands. plunger, ways to get -- protect the drug and get the drug injected into the body. sonali: how much does it matter to have more subsidy for an industry like that via insurance, and how would that be impacting you? stephan: clearly there is tremendous growth especially in the u.s., the model is at a high price point. overtime discounts being made. i think...
0
0.0
tv
eye 0
favorite 0
quote 0
. >> fox business alert, the parent company of novo nordisk of diabetes and weight loss of ozempic andg manufacture for the 16.5 billion in cash and debt it's a company that provides filled finished services to novo nordisk. their factories filled the syringe is for the wildly obesity drug in the purchase would enable novo to boost output, noble holdings will pay $62.50 a share above the current price of 59 - 59 as part of the deal novo nordisk which is hitting an all-time high agreed to buy three of the manufacturing sites from novo holding for $11 billion. critical event management software company ever bridge surging 18.5% bought out by thoma bravo in an all-cash deal with one and half billion dollars shareholders will get $28.68 per share in cash. were almost they were almost at $20.18 after the software company would become privately held, the transaction expected close in the second quarter of 2024. one of the most reliable dividend growers of the stock market tumbled into the bottom of the s&p at this hour. air products and chemicals is losing 15% after posting first-quarter ear
. >> fox business alert, the parent company of novo nordisk of diabetes and weight loss of ozempic andg manufacture for the 16.5 billion in cash and debt it's a company that provides filled finished services to novo nordisk. their factories filled the syringe is for the wildly obesity drug in the purchase would enable novo to boost output, noble holdings will pay $62.50 a share above the current price of 59 - 59 as part of the deal novo nordisk which is hitting an all-time high agreed to...
0
0.0
Feb 6, 2024
02/24
by
BLOOMBERG
tv
eye 0
favorite 0
quote 0
we know that novo nordisk is planning to up its manufacturing capabilities. how big of a constraint is that for them? sam: they continue to say supply or demand outstrips supply and i can see that changing in the next year or two, this is the first some of seems much drug as you can make of what the public will take. slightly convoluted through the holding company that they are related with. that drove the share price of eli lilly. katie: that is sam of bloomberg intelligence, thank you so much. we want to go back to that donald trump news we broke. we will go to kailey leinz from washington. the headline here trumped denied immunity in dce election case by appeals court. what do we know so far? kailey: this is the case the president has been making for some time that he is immune from prosecution in the case special counsel jack smith brought charging him with efforts to overturn the results of the 2020 election that he should be immune from the prosecution as a former president and that the actions he took of the united -- as president should be protected.
we know that novo nordisk is planning to up its manufacturing capabilities. how big of a constraint is that for them? sam: they continue to say supply or demand outstrips supply and i can see that changing in the next year or two, this is the first some of seems much drug as you can make of what the public will take. slightly convoluted through the holding company that they are related with. that drove the share price of eli lilly. katie: that is sam of bloomberg intelligence, thank you so...
0
0.0
Feb 20, 2024
02/24
by
CNBC
tv
eye 0
favorite 0
quote 0
. >> let's finish up with novo nordisk with the anti-obesity drugs here.e for the competitors who are also looking for the market share here? >> you are right. from one space for investors being excited about the an anti-obesity drugs and you see nov novo nordisk at the rise of that. we find that many of the names involved in the space at this stage don't show value left. for the most part, the companies are fairly valued or overvalued. where one door closes, another window opens. we see areas like immunology or oncology which are neglected by investors. >> michael field, market strategist at morningstar. thank you. >>> a quick look at u.s. futures coming back online after the holiday weekend. we are expecting a downward trend. the s&p could fall to the tune of 14 points. that's it for the show. i'm carolin roth. "worldwide exchange" is coming up next. bye-bye. you bring a lot back to civilian life. leadership skills. technical ability. and a drive to serve in new ways. syracuse university's d'aniello institute for veterans and military families has empowe
. >> let's finish up with novo nordisk with the anti-obesity drugs here.e for the competitors who are also looking for the market share here? >> you are right. from one space for investors being excited about the an anti-obesity drugs and you see nov novo nordisk at the rise of that. we find that many of the names involved in the space at this stage don't show value left. for the most part, the companies are fairly valued or overvalued. where one door closes, another window opens....
0
0.0
Feb 6, 2024
02/24
by
CNBC
tv
eye 0
favorite 0
quote 0
. >>> also another stock we are watching is novo nordisk's parent company will buy contractor catalentor $16.5 billion. a heavy try price tag. the acquisition will expand production for wegovy at three sites amid record sales last year. when charlotte spoke to the ceo of novo nordisk last week, he did feel confident in the outlook for supply. no doubt this will help. >>> also in pharma, novartis is set to acquire morphosys for 2.7 billion euro. it will pay cash for the company which it will take private after completion. you see the stock down .30%. morphosys is up 14% on the news. >>> switching to infineon in germany. shares are lower after the chip maker was downgraded. ge german firm posted quarterly net income of 587 million euros. the ceo outlined the issues facing the group. >> i think the market reaction is echoing the current macro challenges we are all witnessing. we have a two tales of the market with auto very strong. we have to confess that is the key driver of the lower guidance for the fiscal year. we have to confess the consumer compute communication markets recovery is
. >>> also another stock we are watching is novo nordisk's parent company will buy contractor catalentor $16.5 billion. a heavy try price tag. the acquisition will expand production for wegovy at three sites amid record sales last year. when charlotte spoke to the ceo of novo nordisk last week, he did feel confident in the outlook for supply. no doubt this will help. >>> also in pharma, novartis is set to acquire morphosys for 2.7 billion euro. it will pay cash for the company...
0
0.0
tv
eye 0
favorite 0
quote 0
stuart: novo nordisk. lauren: their parents are making injection pen company and the like. $6.5 billion is the price tag. popular weight loss and diabetic drugs are injectables and this is a way for them to increase production. stuart: i'm waiting for the pill version. lauren: much easier. stuart: it's coming along as i understand it. i'll do the pill. lauren: production of syringes and the like. stuart: novo nordisk is the most valuable in europe. lauren: imagine that. stuart: new study shows there's a link between smoking marijuana and asthma in children. do we understand the full impact of legalizing weed? i'll get to dr. marc siegle's opinion on that within. former trump official shot and killed during a carjacking in washington dc. dc is riddled with crime. really terrible stuff. we'll have a report on it too. u.s. launch strike with houthi rebels and forces in yes, ma'am and national security adviser jake sullivan insists the u.s. is not looking for a wider war, watch this. >> united states will step
stuart: novo nordisk. lauren: their parents are making injection pen company and the like. $6.5 billion is the price tag. popular weight loss and diabetic drugs are injectables and this is a way for them to increase production. stuart: i'm waiting for the pill version. lauren: much easier. stuart: it's coming along as i understand it. i'll do the pill. lauren: production of syringes and the like. stuart: novo nordisk is the most valuable in europe. lauren: imagine that. stuart: new study shows...
0
0.0
Feb 5, 2024
02/24
by
CNBC
tv
eye 0
favorite 0
quote 0
always know these things -- but i was not aware that novo holdings, which is a part of the novo nordiskly manages the assets of this foundation, which has over $100 billion in assets, is the controlling shareholder of the company that we also talk about so often, novo nordisk itself. why do we talk about it? because of glp-1s. its big drugs, ozempic and wegovy. >> wasn't it quite weird that that one entity bought the three plants? >> yes, the deal is, as such, premium deal for catalent, which has been a problematic company. and then immediately, they're selling three large manufacturing facilities. they own many more than that. selling for $11 billion to novo nordisk, which would seem to put them in a position to meet the ever-growing demand for their products. they're paying quite a price for those three facilities. >> elliott partners, mark steinberg, the person has wide-ranging interests. >> apparently he's a renaissance man. >> yes, he's a renaissance man, but i'll tell you one thing about this deal, carl. let's cut to the chase. the demand for these products are insane. some of the
always know these things -- but i was not aware that novo holdings, which is a part of the novo nordiskly manages the assets of this foundation, which has over $100 billion in assets, is the controlling shareholder of the company that we also talk about so often, novo nordisk itself. why do we talk about it? because of glp-1s. its big drugs, ozempic and wegovy. >> wasn't it quite weird that that one entity bought the three plants? >> yes, the deal is, as such, premium deal for...
0
0.0
Feb 8, 2024
02/24
by
BLOOMBERG
tv
eye 0
favorite 0
quote 0
katie: that was part of my conversation with the ceo of novo nordisk.ompany we are keeping our eyes on. edge well shares the companies after beating profit and sales estimates in the first quarter. joining us now is rob little. so you reported yesterday seen the wall street price targets raised in reaction to that. i want to talk about the international consumer because if you look at the earnings, edge well saw its international business outgrow the demented u.s. business by proximally double the rate. a lot of that came from germany and japan. is that international strength or u.s. weakness? >> good morning. it's good to be with you. it's more about international strength in u.s. weakness. let's start in the u.s., drastically in the u.s. our categories are healthy at the low single-digit rates. we expect to grow in line with the categories this year, u.s. to mystically. we see growth domestically here in the u.s. so it's not like there's an issue here in the u.s.. but outside the u.s. particularly some of the asian markets and latin america we are sti
katie: that was part of my conversation with the ceo of novo nordisk.ompany we are keeping our eyes on. edge well shares the companies after beating profit and sales estimates in the first quarter. joining us now is rob little. so you reported yesterday seen the wall street price targets raised in reaction to that. i want to talk about the international consumer because if you look at the earnings, edge well saw its international business outgrow the demented u.s. business by proximally double...
0
0.0
Feb 8, 2024
02/24
by
KSTS
tv
eye 0
favorite 0
quote 0
anuncio un acuerdo de 16 mil 500 millones de dolares para adquirir catalan, acuerdo que permitira a novoplantas de fabricacion en italia, belgica y estados unidos para la doctora adilia garces, quien aplica la inyeccion para la perdida de peso, ya se esta enfrentando a varios retos. >> hemos tomado la prevision de tener suficiente para cubrir las necesidades de nuestros pacientes que estan acudiendo a nuestra clinica. >> segun el centro para el control de enfermedades, cerca de 38 millones de estadounidenses padecen de diabetes tipo 2 y tambien enfrentan el reto de la escasez. >> si, en algunas ocasiones hemos tenido que cambiar temporalmente los medicamentos hasta que las farmacia nos diga que ya tiene el medicamento disponible para esos pacientes. >> no va a ser indicado que el incremento en su capacidad de produccion derivado del acuerdo con catalan no se materializara hasta la demanda de medicamentos glp-1 continuara excediendo la oferta durante este ano. >> asi que aranza, la escasez continuara. >> ojala y que se pueda resolver rapidamente gracias por este reporte sonia y que le par
anuncio un acuerdo de 16 mil 500 millones de dolares para adquirir catalan, acuerdo que permitira a novoplantas de fabricacion en italia, belgica y estados unidos para la doctora adilia garces, quien aplica la inyeccion para la perdida de peso, ya se esta enfrentando a varios retos. >> hemos tomado la prevision de tener suficiente para cubrir las necesidades de nuestros pacientes que estan acudiendo a nuestra clinica. >> segun el centro para el control de enfermedades, cerca de 38...
0
0.0
Feb 5, 2024
02/24
by
CNBC
tv
eye 0
favorite 0
quote 0
. >> hey, scott catalan is harder as -- novo nordisk's parent company says it will by the parent -- in a deal worth 11 and a half billion dollars excluding debt. novo nordisk will then buy three of the companies sites from its parent to boost manufacturing capacity, for its blockbuster weight loss drug wegovy, in dallas, we're in pharma, more forces is surging as reports that novartis is in talks to buy the cancer treatment company. the report doesn't include a potential price, but more forces currently has market cap of roughly two billion dollars. shares are having their best day ever, up some 58%, as numbers trades along the flat line. >> it, but we'll be back to shortly. pippa stevens, thank you. we're just getting started here on closing bell. up next, giving out the fed, jpmorgan asset management, gabriela santos is with us. mapping out her rate cut forecast and of course the playbook to. we are live from the new york stock exchange, you are watching closing bell on cnbc. ♪♪ whoo! ♪♪ light work! ♪♪ next victims. ♪♪ you ready for this? ♪pump up the jam pump it up♪ your record labe
. >> hey, scott catalan is harder as -- novo nordisk's parent company says it will by the parent -- in a deal worth 11 and a half billion dollars excluding debt. novo nordisk will then buy three of the companies sites from its parent to boost manufacturing capacity, for its blockbuster weight loss drug wegovy, in dallas, we're in pharma, more forces is surging as reports that novartis is in talks to buy the cancer treatment company. the report doesn't include a potential price, but more...
0
0.0
Feb 8, 2024
02/24
by
CNBC
tv
eye 0
favorite 0
quote 0
. >>> coming up, so much focus on lilly and novo nordisk, is there any room for new prlayers? the company looking to tip the scales, next. >>> plus, more earnings action. affirm and pinterest on the move after reporting results. we'll get the details and interview with the pinterest ceo bill ready straight ahead. you're watching "fast money" live from the nasdaq market site in times square. back right after this. ♪♪ ♪♪ ♪♪ ♪♪ ♪♪ switch to shopify and sell smarter at every stage of your business. take full control of your brand with your own custom store. scale faster with tools that let you manage every sale from every channel. and sell more with the best converting checkout on the planet. a lot more. take your business to the next stage when you switch to shopify. personalized financial advice from ameriprise can do more than help you reach your goals. -you can make this work. -we can make this work. it can help you reach them with confidence. no wonder more than 9 out of 10 of our clients are likely to recommend us. ameriprise financial. advice worth talking about. >>> welcom
. >>> coming up, so much focus on lilly and novo nordisk, is there any room for new prlayers? the company looking to tip the scales, next. >>> plus, more earnings action. affirm and pinterest on the move after reporting results. we'll get the details and interview with the pinterest ceo bill ready straight ahead. you're watching "fast money" live from the nasdaq market site in times square. back right after this. ♪♪ ♪♪ ♪♪ ♪♪ ♪♪ switch to shopify...
0
0.0
Feb 29, 2024
02/24
by
CNBC
tv
eye 0
favorite 0
quote 0
. >>> you've now heard a lot about the fabled glp-1s, the weight loss drugs from eli lilly and novo nordiskstorm. that's why i can't wait to see tonight's documentary about these particular drugs by my colleague melissa lee. it's called "the big shot. and it's on tonight at 10:00 p.m. since this is "mad money" i want to talk about the best way to invest in this amazing wave sweeping the globe first as the documentary shows these drugs are big, and i mean really big in this country more than a third of our population's obese, more than 2/3 overweight that's a lot more than the 5 billion people that are currently taking these drugs second, what matters for the most isn't demand, it's supply eli lilly's the only company that can afford to provide the supply of these drugs and they're doing it by building necessary plants novo nordisk doesn't even have money to do it nor can viking therapeutics everyone's so excite about even though their drug's only in phase two and their share offering today cratered the stock. that's why i stand by the idea i've been hearing from legendary investor ken lango
. >>> you've now heard a lot about the fabled glp-1s, the weight loss drugs from eli lilly and novo nordiskstorm. that's why i can't wait to see tonight's documentary about these particular drugs by my colleague melissa lee. it's called "the big shot. and it's on tonight at 10:00 p.m. since this is "mad money" i want to talk about the best way to invest in this amazing wave sweeping the globe first as the documentary shows these drugs are big, and i mean really big in...
0
0.0
Feb 29, 2024
02/24
by
CNBC
tv
eye 0
favorite 0
quote 0
novo nordisk up nearly 70% more on those stocks to watch right after the break.g to find a doctor when i'm hallucinating? what about zocdoc? so many options. yeah, and dr. xichun even takes your sketchy insurance. xi-chun, xi-chun, xi-chun! you've got more options than you know. book now. sometimes, the lows of bipolar depression feel darkest before dawn. with caplyta, there's a chance to let in the lyte™. caplyta is proven to deliver significant relief across bipolar depression. unlike some medicines that only treat bipolar i, caplyta treats both bipolar i and ii depression. and in clinical trials, movement disorders and weight gain were not common. call your doctor about sudden mood changes, behaviors, or suicidal thoughts. antidepressants may increase these risks in young adults. elderly dementia patients have increased risk of death or stroke. report fever, confusion, stiff or uncontrollable muscle movements which may be life threatening or permanent. these aren't all the serious side effects. caplyta can help you let in the lyte™. ask your doctor about caply
novo nordisk up nearly 70% more on those stocks to watch right after the break.g to find a doctor when i'm hallucinating? what about zocdoc? so many options. yeah, and dr. xichun even takes your sketchy insurance. xi-chun, xi-chun, xi-chun! you've got more options than you know. book now. sometimes, the lows of bipolar depression feel darkest before dawn. with caplyta, there's a chance to let in the lyte™. caplyta is proven to deliver significant relief across bipolar depression. unlike some...
0
0.0
Feb 29, 2024
02/24
by
CNBC
tv
eye 0
favorite 0
quote 0
ro roche and novo nordisk. what do you expect?> i think the thing we're focused on for novo next week is any updates on the early stage pipeline. will they talk about the things they have going on in the pill form. wegovy and ozempic are shots. novo has a deal to purchase a drug manufacturer. they are still ongoing with the closing of that deal. pipeline and supply is with a investors are focused on. >> catalen, it was involved wit the vaccines. they are looking to expand now. i know you don't cover vikings therapeutics and zealand. what about those companies? are they game changers? >> it will get more competitive. these are the biggest markets and more companies will try to catch up to novo and eli lilly. we think those two leaders have such a great advantage so far that the viking data and zealand data is similar to novo and eli lilly. novo and eli lilly are in phase three. novo's next-generation drug promised a 25% will see data la year. >> 20% of u.s. kids overweight. could be a big runway for the drugs. emily, thank you for
ro roche and novo nordisk. what do you expect?> i think the thing we're focused on for novo next week is any updates on the early stage pipeline. will they talk about the things they have going on in the pill form. wegovy and ozempic are shots. novo has a deal to purchase a drug manufacturer. they are still ongoing with the closing of that deal. pipeline and supply is with a investors are focused on. >> catalen, it was involved wit the vaccines. they are looking to expand now. i know...
0
0.0
Feb 15, 2024
02/24
by
CNBC
tv
eye 0
favorite 0
quote 0
we see names from novo nordisk of the world go up because that is what people want to invest in. >> sarahshowing the audience of the mega cap tech of the market over the last year. you know, the equal wait is up in the mid single digits. what does that say about the strength of the market? s&p 500 equal weight up 3.5% the last year. what does that say to you about the market and the lack of breadth in it and the direction it will take for the year? >> i like a wider rally. i like it when he everything is doing well and not just one sector, particularly a sector that relies on future and growth and hope and reality. the reality is there is a lot of names in that s&p 500 that are not as relevant and legacy names that have been public for a long time or staying public. if you are a small railroad that is public, maybe all of a sudden, this will not be the most relevant time for you. i don't think it is necessarily bad to see that narrative. i would like it to broaden out. >> we have to goatet out of her. berkshire trimming its position in apple. big deal or little deal? >> i think anything t
we see names from novo nordisk of the world go up because that is what people want to invest in. >> sarahshowing the audience of the mega cap tech of the market over the last year. you know, the equal wait is up in the mid single digits. what does that say about the strength of the market? s&p 500 equal weight up 3.5% the last year. what does that say to you about the market and the lack of breadth in it and the direction it will take for the year? >> i like a wider rally. i...
0
0.0
Feb 1, 2024
02/24
by
CNBC
tv
eye 0
favorite 0
quote 0
two positioned to capture 80% of the market novo nordisk which makes wegovy and ozempic.as a phase one drug with less frequent administration >> tiffany, we have to leave it there. great to see you thank you very much. one more quick look at futures in the green across the bod.ar that will do it for us "squawk box" is up next. [innogue] another destination wedding? why can't they use my backyard?! with empower, we get all of our financial questions answered. so we don't have to worry. empower what's next. in order for small businesses to thrive, they need to be smart, efficient, savvy. making the most of every opportunity. that's why comcast business is introducing the small business bonus. for a limited time you can get up to $1000 prepaid card with qualifying internet. yup, $1000. so switch to business internet from the company with the largest fastest reliable network. give your business a head start in 2024 with this great offer. plus, ask how to get up to $1000 prepaid card with qualifying internet. >>> good morning events in washington impacting the world of busines
two positioned to capture 80% of the market novo nordisk which makes wegovy and ozempic.as a phase one drug with less frequent administration >> tiffany, we have to leave it there. great to see you thank you very much. one more quick look at futures in the green across the bod.ar that will do it for us "squawk box" is up next. [innogue] another destination wedding? why can't they use my backyard?! with empower, we get all of our financial questions answered. so we don't have to...
0
0.0
Feb 26, 2024
02/24
by
CNBC
tv
eye 0
favorite 0
quote 0
they have, according to goldman sachs, accounted for 50% of the gains on the stoxx 600 with novo nordisk and asml among those. we will see if the granolas can continue to power us to new highs. a quick check of the sectors this morning. we are seeing autos and oil and gas and basic resources are pulling us lower here. basic resources on the back of the pressure with metal prices off 1.9%. on the other side of the board, financial services and technology and insurance showing very modest gains. frank, back to you. >> carolin roth with the granola trade during the breakfast hour in the u.s. thank you. >>> turning back to the markets. investors awaiting inflation tests from the u.s. and europe and japan to refine the path for future rate moves. the core pce is due on thursday. forecasts call for a rise of 0.4% in january following the hotter than expected read on consumer and prices with the cpi and ppi. traders pushed out the timing of the first rate cut to june with odds at 66%. there are several fed officials speaking this week who could repeat their mantra. joining me now is ben emons a
they have, according to goldman sachs, accounted for 50% of the gains on the stoxx 600 with novo nordisk and asml among those. we will see if the granolas can continue to power us to new highs. a quick check of the sectors this morning. we are seeing autos and oil and gas and basic resources are pulling us lower here. basic resources on the back of the pressure with metal prices off 1.9%. on the other side of the board, financial services and technology and insurance showing very modest gains....
0
0.0
Feb 7, 2024
02/24
by
BLOOMBERG
tv
eye 0
favorite 0
quote 0
later today on health care, i will be speaking with the ceo of novo nordisk at 12:30 p.m.ork time. still ahead on this program, the companies making the most social buzz today. this is bloomberg. ♪ wealth-changing question -- are you keeping as much of your investment gains as possible? high taxes can erode returns quickly, so you need a tax-optimized portfolio. at creative planning, our money managers and specialists work together to make sure your portfolio and wealth are managed in a tax-efficient manner. it's what you keep that really matters. why not give your wealth a second look? book your free meeting today at creativeplanning.com. creative planning -- a richer way to wealth. katie: time for social climbers, a look at the stocksthat is a s. you can follow all the latest buzz on the bloomberg terminal. coming up, the carlisle group overhauling dealmakers to free up cash flow as it plans a buyback. we speak to the company's ceo next. this is bloomberg. ♪ y coach in the chase mobile® app. use it to set and track your goals, big and small... and see how changes you mak
later today on health care, i will be speaking with the ceo of novo nordisk at 12:30 p.m.ork time. still ahead on this program, the companies making the most social buzz today. this is bloomberg. ♪ wealth-changing question -- are you keeping as much of your investment gains as possible? high taxes can erode returns quickly, so you need a tax-optimized portfolio. at creative planning, our money managers and specialists work together to make sure your portfolio and wealth are managed in a...
0
0.0
Feb 27, 2024
02/24
by
CNBC
tv
eye 0
favorite 0
quote 0
novo nordisk is up 0.5% in copenhagen trade.teve spoke to sharon bell from goldman sachs who coined the acronym and said what sets the stocks apart an. >> the s&p trades at 21. they had similar growth. they are not super expensiiexpe. i think these companies have very good balance sheets and many have cash on their balance sheets just like the magnificent seven companies. stable growth and good margins. they hedeserve premium. >> bell talked about which central bank will cut rates first. take a listen. >> we expect the ecb to cut from april. a bit before the fed and bank of england. we will see if that happens. we had a weak set of data in europe the last couple quarters. on balance, that supports equities. >>> moving on. jamie dimon is warning that the markets are too optimistic for a chance of the soft economy. speaking to cnbc, dimon is concerned about a number of economic factors. >> 70% or 80% chance we will have a soft landing. i give it half that. we may very well have one, but pres the market thinks it is higher. the oth
novo nordisk is up 0.5% in copenhagen trade.teve spoke to sharon bell from goldman sachs who coined the acronym and said what sets the stocks apart an. >> the s&p trades at 21. they had similar growth. they are not super expensiiexpe. i think these companies have very good balance sheets and many have cash on their balance sheets just like the magnificent seven companies. stable growth and good margins. they hedeserve premium. >> bell talked about which central bank will cut...
0
0.0
Feb 6, 2024
02/24
by
CNBC
tv
eye 0
favorite 0
quote 0
there is a capacity strength problem for lilly and/or even novo nordisk over time. >> for sure.e seeing. $11 billion just, you know, to make one drug essentially. it will be more over time. but i think novo mentioned last year they were going to set aside $6 billion, so they almost doubled that number with the deal supposing this goes through with ftc et cetera. lilly has earmarked $3 billion. this is the most substantial manufacturing or capacity build out we've seen in the drug industry, maybe ever. certainly since covid. i think these drugs will, obviously, clear that hurdle over the next few years. >> will they be the biggest selling drugs of all time? >> they will be. i think the biggest kind of impediment is going to be pay or push back. insurance companies saying enough is enough. who needs this versus who doesn't. we're not there yet and haven't scratched the surface in terms of how big the drugs are going to get. >> in ai, they talk about the chase is crowding out other crowd spending. is this clouding out other growth stories in cancer? >> from an investment standpoint
there is a capacity strength problem for lilly and/or even novo nordisk over time. >> for sure.e seeing. $11 billion just, you know, to make one drug essentially. it will be more over time. but i think novo mentioned last year they were going to set aside $6 billion, so they almost doubled that number with the deal supposing this goes through with ftc et cetera. lilly has earmarked $3 billion. this is the most substantial manufacturing or capacity build out we've seen in the drug...
0
0.0
Feb 19, 2024
02/24
by
FBC
tv
eye 0
favorite 0
quote 0
. >> we are talking about over $1000 a month obviously you have to be well-off to afford that novo nordiskprofits, they're trying to catch up to the shortage issue on the drugs wo wegovy and ozempic. it's more than glp-1 and what jerry was saying it's too hormones in git as well, here's what i want to talk about this. i don't look at obesity as separate from other medical problems, listen if you are obese and we have an obesity epidemic in the united states are not only more prone to diabetes you're more prone to high blood pressure, heart disease, cancer and diabetes so i look at is a constellation of things i need people's weight to go down, how do i get there, were not exercising enough as a nation our diets are terrible we have too many chemicals in our diet and too many carbohydrates is not the every whether the country needs to be on wegovy but the pockets that need it i'm arguing that we needed to protect against other diseases that is not how insurance companies want to see it and that's not how the state wants to see it but that's the rea reality. ashley: with that happy thought i
. >> we are talking about over $1000 a month obviously you have to be well-off to afford that novo nordiskprofits, they're trying to catch up to the shortage issue on the drugs wo wegovy and ozempic. it's more than glp-1 and what jerry was saying it's too hormones in git as well, here's what i want to talk about this. i don't look at obesity as separate from other medical problems, listen if you are obese and we have an obesity epidemic in the united states are not only more prone to...
0
0.0
Feb 26, 2024
02/24
by
FBC
tv
eye 0
favorite 0
quote 0
. >> two weight loss drugs that have done extremely well in the past year, novo nordisk and eli lily been on a tear. >> that the biggest company in europe. are they getting competition. >> another european company. >> a danish company zealand pharmaceutical i think that would be out of new zealand but it's not. they have a liver inflammation drug, they did trials, 83% of adult saw positive results this is tied to the weight loss drug market goldman says the weight loss in the u.s. could boost gdp by 1% if there are 60 million americans actually take these and some analysts are predicting that the market for weight loss drugs would reach $100 billion per year by the end of the decade, if more drug companies coming with different needs for the weight loss drugs the micro does every morning to get weight loss drug to treat this and treat that and then you lose weight. >> if you can make it into a pill rather than the injection then i am in i see that happening, who would it take a pill like that, me for example. stuart: let's go to domino's pizza a great report, now they're up 8%, what
. >> two weight loss drugs that have done extremely well in the past year, novo nordisk and eli lily been on a tear. >> that the biggest company in europe. are they getting competition. >> another european company. >> a danish company zealand pharmaceutical i think that would be out of new zealand but it's not. they have a liver inflammation drug, they did trials, 83% of adult saw positive results this is tied to the weight loss drug market goldman says the weight loss...
0
0.0
Feb 27, 2024
02/24
by
FBC
tv
eye 0
favorite 0
quote 0
the new potential competition here impacting eli lilly and ozempic maker novo nordisk.nt. we should rook at zoom -- looked at zoom shares. the sid owe conferencing king on pace for its largest percentage increase in more than a year with. zoom proving it's more than just a pandemic era darling after reporting a fourth quarter revenue beat and announcing a $1.5 billion share buyback program. norwegian cruise line, it is sailing all the way to the top of the s&p 500 after forecasting a first quarter profit above wall street estimates. the cruise line operator cited cost control, higher ticket prices and steady demand for cruises globally, and that is enough to punch this stock 19% higher. no surprise here that the news has rival royal caribbean and carnival also floating higher. you've got carnival up 7.5%, royal carrib up 3%. >>> jetblue air aways and spirit airlines both flying a bit higher after showing they be will fight to overturn a judge's ruling blocking their $3.8 billion merger. the airlines say the u.s. district judge, quote, improperly chose to elevate the int
the new potential competition here impacting eli lilly and ozempic maker novo nordisk.nt. we should rook at zoom -- looked at zoom shares. the sid owe conferencing king on pace for its largest percentage increase in more than a year with. zoom proving it's more than just a pandemic era darling after reporting a fourth quarter revenue beat and announcing a $1.5 billion share buyback program. norwegian cruise line, it is sailing all the way to the top of the s&p 500 after forecasting a first...
0
0.0
Feb 20, 2024
02/24
by
KNTV
tv
eye 0
favorite 0
quote 0
. >> reporter: in a statement, wegovy's maker novo nordisk said, the decision to prescribe an anti-obesityn. >> this is beautiful. demi reached her goal weight and she's looking forward to prom this spring. >> i don't think you have to look a certain way. but if it is going to make you feel better, then do it. >> reporter: vicky nguyen, nbc news. >>> in today's daily health, exercise is great for everyone, right, but a new study shows that the benefits might be even better for women than men. the national study published this week, finds regular exercise decreases the risk of mortality in women even if they worked out for less time than men did. aria joins me now. i love this headline. walk us through the results. what are they talking about when they say regular exercise. >> the first part of the study looked at aerobic activities. women and men when they did the same level of activities, 2.5 hours of moderate exercise, women actually had 24% lower risk of dying over the study period. whereas men had 15% lower risk. so that's the first part of the study. the second part looked at these mu
. >> reporter: in a statement, wegovy's maker novo nordisk said, the decision to prescribe an anti-obesityn. >> this is beautiful. demi reached her goal weight and she's looking forward to prom this spring. >> i don't think you have to look a certain way. but if it is going to make you feel better, then do it. >> reporter: vicky nguyen, nbc news. >>> in today's daily health, exercise is great for everyone, right, but a new study shows that the benefits might be...
0
0.0
Feb 29, 2024
02/24
by
CNBC
tv
eye 0
favorite 0
quote 0
. >>> coming up, shares of novo nordisk are up 70% over the last year. ozempic demand soaring. favor, we celebrate black heritage, here's m&t bank ceo, reni■jones, sharing his story. >> as a black ceo of a fortune 500 company, and maybe an exception, but it's important to remember that there are many exceptional people who inspire others every day. black heritage munch gives us the opportunity to celebrate many exceptional, for extraordinary people in our black and brown communities across north america. [sfx: wind, rain and rolling thunder] nobody's born with grit. british announcer: rose is really struggling. it's something you build over time. american announcer: that's 21 missed cuts in a row. [car trunk slammed shut] for 88 years, morgan stanley has offered clients determination and forward thinking to create the future... crowd: stop it! ...only you can see. american announcer: rose, back in the winner's circle. [crowd cheers] [music out] this thing, it's making me get an ice bath again. what do you mean? these straps are mind-blowing! they collect hundreds of data points
. >>> coming up, shares of novo nordisk are up 70% over the last year. ozempic demand soaring. favor, we celebrate black heritage, here's m&t bank ceo, reni■jones, sharing his story. >> as a black ceo of a fortune 500 company, and maybe an exception, but it's important to remember that there are many exceptional people who inspire others every day. black heritage munch gives us the opportunity to celebrate many exceptional, for extraordinary people in our black and brown...
0
0.0
Feb 29, 2024
02/24
by
CNBC
tv
eye 0
favorite 0
quote 0
nordisk.where are compounding pharmacies getting these active ingredients? >> the big issues with obtaining compounded semaglutide, the glp-1ing is, is -- i don't knor these molecules are coming from. i don't know how pure they are what else is being added i have more questions right now than i have answers. >> that was a look at my documentary "big shot: the ozempic revenue," which premieres tonight on cnbc. as a business of fda-approved weight loss drugs booms, so does the business of copying them you don't know what you're getting in these compounded versions let's bring in dr. kavita patel, a medical contributor, a former white house policy director. great to have you with us. the problem has arisen because there are shortages, because the brand name drugs are so expensive. there's questions about access in terms of insurance, and whether or not insurance companies will actually cover these drugs. when do you anticipate these factors to sort of abate >> well, i think it's going to be awhil
nordisk.where are compounding pharmacies getting these active ingredients? >> the big issues with obtaining compounded semaglutide, the glp-1ing is, is -- i don't knor these molecules are coming from. i don't know how pure they are what else is being added i have more questions right now than i have answers. >> that was a look at my documentary "big shot: the ozempic revenue," which premieres tonight on cnbc. as a business of fda-approved weight loss drugs booms, so does...
0
0.0
Feb 26, 2024
02/24
by
CNBC
tv
eye 0
favorite 0
quote 0
a danish pharma stock that isn't novo nordisk is surging on positive drug results. it means for competition in the space. >>> and some afterhours action to bring you. shares of zoom and workday on the move after reporting results. the details out of those quarters when "fast money" returns. back in two. >>> missed a moment of "fast?" catch us any time on the go. follow the "fast money" podcast. we're back right after this. (inner monologue) my kids don't know what they want. you know who knows what she wants? me! i want a massage, in amalfi, from someone named giancarlo. and i didn't live in that shoebox for years. not just— with empower, we get all of our financial questions answered. so you don't have to worry. i guess i'll get the caviar... just kidding. join 18 million americans and take control of your financial future with a real time dashboard and real live conversations. empower. what's next. every day, more dog people, and more vets are deciding it's time for a fresh approach to pet food. they're quitting the kibble. and kicking the cans. and feeding their
a danish pharma stock that isn't novo nordisk is surging on positive drug results. it means for competition in the space. >>> and some afterhours action to bring you. shares of zoom and workday on the move after reporting results. the details out of those quarters when "fast money" returns. back in two. >>> missed a moment of "fast?" catch us any time on the go. follow the "fast money" podcast. we're back right after this. (inner monologue) my...
0
0.0
Feb 6, 2024
02/24
by
KTVU
tv
eye 0
favorite 0
quote 0
novo nordisk, biggest shareholder is buying catalan, one of the world's largest drug manufacturing companiesal is worth $16.5 billion. now the company is trying to build a larger supply chain after facing shortages of both its wegovy and ozempic shots. stocks sliding on wall street today, traders delaying their expectations on when the fed might lower those interest rates, with reports that the economy remains strong, the dow dropped more than 274 points. the nasdaq was down 31, and the s&p also in the red, down 15 points. federal reserve chair jerome powell suggesting in an interview that rate cuts not likely to start next month as some investors had hoped. still to come, the death toll in chile, now more than 100 following massive wildfires that destroyed entire neighborhoods, plus us missiles strike houthi targets in yemen as the white house says its response to the drone strike in jordan that killed three americans is just beginning. >> i'm rebecca caster in washington with the latest coming up and it's still a few years away, but we now have the details about where the 2026 world cup ma
novo nordisk, biggest shareholder is buying catalan, one of the world's largest drug manufacturing companiesal is worth $16.5 billion. now the company is trying to build a larger supply chain after facing shortages of both its wegovy and ozempic shots. stocks sliding on wall street today, traders delaying their expectations on when the fed might lower those interest rates, with reports that the economy remains strong, the dow dropped more than 274 points. the nasdaq was down 31, and the s&p...
0
0.0
Feb 27, 2024
02/24
by
CNBC
tv
eye 0
favorite 0
quote 0
lily is -- does it still have the pole position hereeven against novo nordisk. >> so, yes. at this point it's still a due oply. we are very bullish on lily and think that both can exist in this market. the key here is the data that they have but also the manufacturing and the supply that they're able to bring to the market. remember, they invested billions upon billions, novo just bought facilities. lil li investing heavily in north carolina. every vile made will be used by patients in the market. >> evan, yesterday we had the discussion as well on healthcare as we're looking at this all week and the analysts we had on was talking about the pbms and how they may be beneficiaries. what is your view on that space? >> so pbms are interesting. i highlight one of the themes this year is pharma out of the crosshairs. right? they had the ira last year, we have seen that play out. but it's really pbm -- i know that some legislation didn't pass. but it's pretty clear that there's going to be a more scrutiny around the pbms and where the rebates and discounts are going. this is gener
lily is -- does it still have the pole position hereeven against novo nordisk. >> so, yes. at this point it's still a due oply. we are very bullish on lily and think that both can exist in this market. the key here is the data that they have but also the manufacturing and the supply that they're able to bring to the market. remember, they invested billions upon billions, novo just bought facilities. lil li investing heavily in north carolina. every vile made will be used by patients in...
0
0.0
Feb 29, 2024
02/24
by
KRON
tv
eye 0
favorite 0
quote 0
all things considered novo nordisk and are the companies. this is probably the biggest news story. financial, a story in the world ever lost rugs to the weight class for people like me. >> you think that every revolutionizing and a lot of different areas, i guess party are they already are the can now get when you can get them prescribed. unlike the hymns online where it can be done. discreetly. i think the uses are going to go up even higher off-label. wow. okay. all right. >> and then will round out the today segment with a look at event tourism against taylor swift has something to do with >> yeah, i'm going to london this summer. my wife wants to see the killers and i want to see a soccer game. that's an event. tate haze in singapore first shows this weekend right after bruno mars just finished and sheer unfinished. coldplay finished coldplay sold 200,000 tickets which was a world record. i think that in one day the lion city, singapore's typically known for business. but now turning into an event for tourism. they're going to add about 10% of gdp with all that worst time on mu
all things considered novo nordisk and are the companies. this is probably the biggest news story. financial, a story in the world ever lost rugs to the weight class for people like me. >> you think that every revolutionizing and a lot of different areas, i guess party are they already are the can now get when you can get them prescribed. unlike the hymns online where it can be done. discreetly. i think the uses are going to go up even higher off-label. wow. okay. all right. >> and...
0
0.0
Feb 1, 2024
02/24
by
KTVU
tv
eye 0
favorite 0
quote 0
novo nordisk initially marin touted the drugs as a treatment for diabetes, and now it has a valuationbillion. that, according to cnbc, which analyzed data from the london stock exchange group novo, is now europe's largest company, and it says it plans to boost us supplies of wegovy. >> lawmakers on capitol hill address the increasing prices of college tuition. what many say they want to do to change not only the process of getting into schools, but also the process of taking out loans. >> stanford women's basketball, making a run toward all that march madness, the teams starting to take over those power ratings just a week after their coach hit the all time wins record. >> and we are tracking some rainfall, the heaviest rainfall still moving into the bay area over the next 2 or 3 hours. we'll track that. we'll look at the winds that are gusting and the forecast. i'll see you back here. >> first, the breaking news. we're continuing to follow a police shooting in san francisco tonight involving the chp. we're getting our first oo righ (vo) fargo, is the new virtual assistant from wells
novo nordisk initially marin touted the drugs as a treatment for diabetes, and now it has a valuationbillion. that, according to cnbc, which analyzed data from the london stock exchange group novo, is now europe's largest company, and it says it plans to boost us supplies of wegovy. >> lawmakers on capitol hill address the increasing prices of college tuition. what many say they want to do to change not only the process of getting into schools, but also the process of taking out loans....
0
0.0
Feb 20, 2024
02/24
by
KNTV
tv
eye 0
favorite 0
quote 0
. >> reporter: in a statement, novo nordisk said, the decision to prescribe an anti-obesity medication prom this spring. >> if it is going to make you feel better, then do it. >> now, as for whether kids are covered by insurance for these drugs, it depends on your plan and what your child is diagnosed with if it is type one diabetes, you will be covered for it without insurance, these meds run about $1,000 a month >> i'm sure there are some parents who are wondering if they could do it for a short-term, just for a boost and not necessarily for the rest of their lives. >> the doctor said that she's asked about it all the time. she's been working with kids for 10 years she says that's not how it works. when you start at 12, you go on it long-term other doctors are wondering if you get to the goal weight, perhaps you can taper off. that's what actually demi will try to do. they will monitor her. if the weight starts to come back on, she's go back on the medicine >> it is interesting you went into it skeptically. and by the time it was finished, you saw the other side of the coin >> it is
. >> reporter: in a statement, novo nordisk said, the decision to prescribe an anti-obesity medication prom this spring. >> if it is going to make you feel better, then do it. >> now, as for whether kids are covered by insurance for these drugs, it depends on your plan and what your child is diagnosed with if it is type one diabetes, you will be covered for it without insurance, these meds run about $1,000 a month >> i'm sure there are some parents who are wondering if...
0
0.0
Feb 6, 2024
02/24
by
CNBC
tv
eye 0
favorite 0
quote 0
and i think what was important was novo nordisk last fall had data for a trial called select, and ithat for a glp-1 drug, it's not just about weight loss. you have things like reduction in cardiovascular death, reduction in stroke, reduction in heart attacks, et cetera. so it really isn't, just weight loss. i think tbreadth of the benefit of these drugs is pretty dramatic. >> it would have been a great one to own for a couple of odomny jeff. go cpa to cover. lucky guy. thank you. "squawk box" will be right back. it's time to feed the dogs real food, not highly processed pellets. the farmer's dog is fresh food made with whole meat and veggies. it's not dry food. it's not wet food. it's just real food. it's an idea whose time has come. at morgan stanley, old school hard work meets bold new thinking. to help you see untapped possibilities and relentlessly work with you to make them real. >>> good morning. markets in focus this hour. we have a can't-miss interview with legendary investor leon cooperman. plus, meta strengthening its labeling of ai content as we get closer to the election.
and i think what was important was novo nordisk last fall had data for a trial called select, and ithat for a glp-1 drug, it's not just about weight loss. you have things like reduction in cardiovascular death, reduction in stroke, reduction in heart attacks, et cetera. so it really isn't, just weight loss. i think tbreadth of the benefit of these drugs is pretty dramatic. >> it would have been a great one to own for a couple of odomny jeff. go cpa to cover. lucky guy. thank you....
0
0.0
Feb 27, 2024
02/24
by
BLOOMBERG
tv
eye 0
favorite 0
quote 0
if we look at something like a novo nordisk and the percentage of the daily stock market represents in just one stock it's much more risky than for example the magnificent seven in the percentage of the stock market. annmarie: the risks of that concentration in the united states is still quite large. 90% of these companies in terms of their chips are tied to taiwan. katrina: i think what we are seeing as they are addressing those already. unfortunately it takes time but time will cure that problem is they reshore manufacturing brain if you take a look at a problem if time can cure your problem you've got to wait it out. i think that's what we are seeing in those markets. >> way too much bullishness. just to set things old limit more balance this morning. inflation risks are skewed to the upside given loose financial conditions. which could keep it higher for longer. heard this from marco last week there is a risk of a narrative turning back from goldilocks to something like 1970's stagflation. lisa: he is not alone and if you look at the margins no one's willing to say 1970's but they
if we look at something like a novo nordisk and the percentage of the daily stock market represents in just one stock it's much more risky than for example the magnificent seven in the percentage of the stock market. annmarie: the risks of that concentration in the united states is still quite large. 90% of these companies in terms of their chips are tied to taiwan. katrina: i think what we are seeing as they are addressing those already. unfortunately it takes time but time will cure that...
0
0.0
Feb 8, 2024
02/24
by
BLOOMBERG
tv
eye 0
favorite 0
quote 0
the novo nordisk ceo says he's been receiving calls from other ceos saying they are scared about it. names but the conversation centered around how the drugs work. the connecticut governor has unveiled plans to challenge new york state's tax role for remote workers -- tax rule for remote workers. the governor's plan aims to encourage residents to file suits against new york state to get tax refunds. lamont says the proposal could generate $200 million annually. jon: next, making the case for credit. >> if the soft landing, and this is key, can the fed cut enough? jon: that conversation around the corner. live from new york, this is bloomberg. ♪ how am i going to find a doctor when i'm hallucinating? what do you think, fever monster? what about zocdoc? zocdoc? dr. castell has a great bedside manner. so many options. but dr. xichun will take your sketchy insurance. xi-chun! xi-chun, xi-chun, xi-chun! thanks, bro! you've got more options than you know. book now. get help reaching your goals with j.p. morgan wealth plan, a digital money coach in the chase mobile® app. use it to set and t
the novo nordisk ceo says he's been receiving calls from other ceos saying they are scared about it. names but the conversation centered around how the drugs work. the connecticut governor has unveiled plans to challenge new york state's tax role for remote workers -- tax rule for remote workers. the governor's plan aims to encourage residents to file suits against new york state to get tax refunds. lamont says the proposal could generate $200 million annually. jon: next, making the case for...
0
0.0
Feb 28, 2024
02/24
by
CNBC
tv
eye 0
favorite 0
quote 0
i'm wondering of the names that are not eli lilly and novo nordisk, who do you like in terms of havinge? you mentioned amgen? how about others? >> amgen on one side, late stage phase two, also zeeland, a company that is a recent metabolic mash data last week. there is also the oral compounds, structure therapeutics, which has data coming up, and there is other interesting modalities that are people are trying to do beyond just glp, melissa. one of those is scala rock, regeneron and scala rock are working on myo statins. some of these drugs improve on losing muscle. there is other small companies like ventix, which works on antiinflammatories. a lot of different companies beyond lilly that i think over this ten years i think are going to be important. >> it seems like it would be an easy acquisition for big pharma to make because they're searching for ways to extend their pipeline, a lot of cash on the balance sheet, a lot of pressure to do something, when you look at the stock price. who do you think are likely candidates for acquisition? >> well, first i would say roche and astrazenec
i'm wondering of the names that are not eli lilly and novo nordisk, who do you like in terms of havinge? you mentioned amgen? how about others? >> amgen on one side, late stage phase two, also zeeland, a company that is a recent metabolic mash data last week. there is also the oral compounds, structure therapeutics, which has data coming up, and there is other interesting modalities that are people are trying to do beyond just glp, melissa. one of those is scala rock, regeneron and scala...
0
0.0
Feb 5, 2024
02/24
by
CNBC
tv
eye 0
favorite 0
quote 0
then there is parent company of novo nordisk saying buy contract drugmaker catalent about $11 billionor filling and packages syringes and injeshgz pins for nouveavo nordisks weight loss d wegovy. shares up by 1 m.8%. >>> bringing in our own mike santoli the recent record run for stocks and whether, of course that can continue. mike santoli at the new york stock exchange. good morning. >> good morning. yeah. this run to a record last week by s&p 500 happened through a gauntlet. market continues to be tested on some of the major premises that got us here. which is one, can good economic news be treated good news by markets? have a bit of rethink on the initiation of potential fed rate cuts by powell and by the data. then, of course, you had some of the choppier big cap tech earnings causing a gut check. uneven. get to a new record. gotten the market to a bit of the upper end of this trend line. kind of pointing this out for a while. you want to take that as a trend since the fall, always projected a little over 5,000. a bit of a maybe culmination moment or stock re-assess it. be mindful
then there is parent company of novo nordisk saying buy contract drugmaker catalent about $11 billionor filling and packages syringes and injeshgz pins for nouveavo nordisks weight loss d wegovy. shares up by 1 m.8%. >>> bringing in our own mike santoli the recent record run for stocks and whether, of course that can continue. mike santoli at the new york stock exchange. good morning. >> good morning. yeah. this run to a record last week by s&p 500 happened through a...
0
0.0
Feb 6, 2024
02/24
by
MSNBCW
tv
eye 0
favorite 0
quote 0
. >> there's a move to nova nordisk to increase supply. >> the parent company of nova nordisk have saidrom $16.5 billion. now it sounds like a hefty price tag, but novo said the deal will be essential to meeting soaring demand for that weight loss drug, wegovy. the acquisition means they can expand production across three manufacturing sites. you may recall last year they diflag supply bottlenecks. when it comes to the production of wegovy, they actually had to restrict access to some u.s. patients. this deal allayed somebody of the concerns and welcome to the analyst community who are hoping they can actually start ramping up supply in a meaningful fashion now. >> lastly, the 66th annual grammy awards notched an impressive 66 million viewers last night. we can give taylor swift plenty of the credit, but this has also been a trend where award shows starting to pick up. dare we say they're in their rebound era? >> you can definitely say that as well as the grammys are concerned. the viewing figures pretty strong from sunday coming in as you say 16.9 million viewers up toing in. that's th
. >> there's a move to nova nordisk to increase supply. >> the parent company of nova nordisk have saidrom $16.5 billion. now it sounds like a hefty price tag, but novo said the deal will be essential to meeting soaring demand for that weight loss drug, wegovy. the acquisition means they can expand production across three manufacturing sites. you may recall last year they diflag supply bottlenecks. when it comes to the production of wegovy, they actually had to restrict access to...